Duchenne muscular dystrophy (DMD) is an X-linked genetic disease characterized by the absence of dystrophin (427 kDa). An approach to eventually restore this protein in patients with DMD is to introduce into their muscles a plasmid encoding dystrophin cDNA. Because the phenotype of the dystrophic dog is closer to the human phenotype than is the mdx mouse phenotype, we have studied the electrotransfer of a plasmid carrying the full-length dog dystrophin (FLDYSdog) in dystrophic dog muscle. To achieve this nonviral delivery, the FLDYSdog cDNA was cloned in two plasmids containing either a cytomegalovirus or a muscle creatine kinase promoter. In both cases, our results showed that the electrotransfer of these large plasmids (∼17 kb) into mouse muscle allowed FLDYSdog expression in the treated muscle. The electrotransfer of pCMV.FLDYSdog in a dystrophic dog muscle also led to the expression of dystrophin. In conclusion, introduction of the full-length dog dystrophin cDNA by electrotransfer into dystrophic dog muscle is a potential approach to restore dystrophin in patients with DMD. However, the electrotransfer procedure should be improved before applying it to humans.
Get full access to this article
View all access options for this article.
References
1.
AiharaH., MiyazakiJ.1998. Gene transfer into muscle by electroporation in vivo. Nat. Biotechnol., 16:867–870.
2.
AndreF.M., GehlJ., SersaG., PreatV., HojmanP., EriksenJ., GolzioM., CemazarM., PavseljN., RolsM.P., MiklavcicD., NeumannE., TeissieJ., MirL.M.2008. Efficiency of high- and low-voltage pulse combinations for gene electrotransfer in muscle, liver, tumor, and skin. Hum. Gene Ther., 19:1261–1271.
BartlettR.J., WinandN.J., SecoreS.L., SingerJ.T., FletcherS., WiltonS., BoganD.J., Metcalf-BoganJ.R., BartlettW.T., HowellJ.M., CooperB.J., KornegayJ.N.1996. Mutation segregation and rapid carrier detection of X-linked muscular dystrophy in dogs. Am. J. Vet. Res., 57:650–654.
5.
BeggsA.H., HoffmanE.P., SnyderJ.R., ArahataK., SpechtL., ShapiroF., AngeliniC., SugitaH., KunkelL.M.1991. Exploring the molecular basis for variability among patients with Becker muscular dystrophy: Dystrophin gene and protein studies. Am. J. Hum. Genet., 49:54–67.
6.
BertrandA., Ngo-MullerV., HentzenD., ConcordetJ.P., DaegelenD., TuilD.2003. Muscle electrotransfer as a tool for studying muscle fiber-specific and nerve-dependent activity of promoters. Am. J. Physiol. Cell. Physiol., 285:C1071–C1081.
7.
Bodles-BrakhopA.M., HellerR., Draghia-AkliR.2009. Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: Current clinical developments. Mol. Ther., 17:585–592.
8.
CampbellK.P., KahlS.D.1989. Association of dystrophin and an integral membrane glycoprotein. Nature, 338:259–262.
9.
ChapdelaineP., MoissetP.A., CampeauP., AsselinI., VilquinJ.T., TremblayJ.P.2000. Functional EGFP–dystrophin fusion proteins for gene therapy vector development. Protein Eng., 13:611–615.
10.
DouglasJ.T.2007. Adenoviral vectors for gene therapy. Mol. Biotechnol., 36:71–80.
11.
ErvastiJ.M., CampbellK.P.1991. Membrane organization of the dystrophin–glycoprotein complex. Cell, 66:1121–1131.
12.
ErvastiJ.M., OhlendieckK., KahlS.D., GaverM.G., CampbellK.P.1990. Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle. Nature, 345:315–319.
13.
FabreE.E., BigeyP., OrsiniC., SchermanD.2006. Comparison of promoter region constructs for in vivo intramuscular expression. J. Gene Med., 8:636–645.
14.
FattoriE., CappellettiM., ZampaglioneI., MennuniC., CalvarusoF., ArcuriM., RizzutoG., CostaP., PerrettaG., CilibertoG., La MonicaN.2005. Gene electro-transfer of an improved erythropoietin plasmid in mice and non-human primates. J. Gene Med., 7:228–236.
15.
FavardC., DeanD.S., RolsM.P.2007. Electrotransfer as a non viral method of gene delivery. Curr. Gene Ther., 7:67–77.
16.
FewellJ.G., MaclaughlinF., MehtaV., GondoM., NicolF., WilsonE., SmithL.C.2001. Gene therapy for the treatment of hemophilia B using PINC-formulated plasmid delivered to muscle with electroporation. Mol. Ther., 3:574–583.
17.
FlintermanM., FarzanehF., HabibN., MalikF., GakenJ., TavassoliM.2009. Delivery of therapeutic proteins as secretable TAT fusion products. Mol. Ther., 17:334–342.
18.
GilbertR., NalbantogluJ., HowellJ.M., DaviesL., FletcherS., AmalfitanoA., PetrofB.J., KamenA., MassieB., KarpatiG.2001. Dystrophin expression in muscle following gene transfer with a fully deleted (“gutted”) adenovirus is markedly improved by trans-acting adenoviral gene products. Hum. Gene Ther., 12:1741–1755.
19.
HagstromJ.E., HeggeJ., ZhangG., NobleM., BudkerV., LewisD.L., HerweijerH., WolffJ.A.2004. A facile nonviral method for delivering genes and siRNAs to skeletal muscle of mammalian limbs. Mol. Ther., 10:386–398.
20.
HarperS.Q., HauserM.A., DellorussoC., DuanD., CrawfordR.W., PhelpsS.F., HarperH.A., RobinsonA.S., EngelhardtJ.F., BrooksS.V., ChamberlainJ.S.2002. Modular flexibility of dystrophin: Implications for gene therapy of Duchenne muscular dystrophy. Nat. Med., 8:253–261.
21.
HoffmanE.P., BrownR.H.Jr., KunkelL.M.1987. Dystrophin: The protein product of the Duchenne muscular dystrophy locus. Cell, 51:919–928.
22.
HojmanP., GisselH., AndreF.M., Cournil-HenrionnetC., EriksenJ., GehlJ., MirL.M.2008. Physiological effects of high- and low-voltage pulse combinations for gene electrotransfer in muscle. Hum. Gene Ther., 19:1249–1260.
23.
JaynesJ.B., JohnsonJ.E., BuskinJ.N., GartsideC.L., HauschkaS.D.1988. The muscle creatine kinase gene is regulated by multiple upstream elements, including a muscle-specific enhancer. Mol. Cell. Biol., 8:62–70.
24.
JiaoS., WilliamsP., BergR.K., HodgemanB.A., LiuL., RepettoG., WolffJ.A.1992. Direct gene transfer into nonhuman primate myofibers in vivo. Hum. Gene Ther., 3:21–33.
25.
MayrhoferP., SchleefM., JechlingerW.2009. Use of minicircle plasmids for gene therapy. Methods Mol. Biol., 542:87–104.
26.
MirL.M.2008. Application of electroporation gene therapy: Past, current, and future. Methods Mol. Biol., 423:3–17.
27.
MirL.M., BelehradekM., DomengeC., OrlowskiS., PoddevinB., BelehradekJ.Jr., SchwaabG., LuboinskiB., PaolettiC.1991. Electrochemotherapy, a new antitumor treatment: First clinical trial. C. R. Acad. Sci. III, 313:613–618.
28.
MirL.M., BureauM.F., GehlJ., RangaraR., RouyD., CaillaudJ.M., DelaereP., BranellecD., SchwartzB., SchermanD.1999. High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proc. Natl. Acad. Sci. U.S.A., 96:4262–4267.
29.
MirandaA.F., BonillaE., MartucciG., MoraesC.T., HaysA.P., DimauroS.1988. Immunocytochemical study of dystrophin in muscle cultures from patients with Duchenne muscular dystrophy and unaffected control patients. Am. J. Pathol., 132:410–416.
30.
MyersE.W., MillerW.1988. Optimal alignments in linear space. Comput. Appl. Biosci., 4:11–17.
31.
OhshimaS., ShinJ.H., YuasaK., NishiyamaA., KiraJ., OkadaT., TakedaS.2009. Transduction efficiency and immune response associated with the administration of AAV8 vector into dog skeletal muscle. Mol. Ther., 17:73–80.
32.
OhtsukaY., UdakaK., YamashiroY., YagitaH., OkumuraK.1998. Dystrophin acts as a transplantation rejection antigen in dystrophin-deficient mice: Implication for gene therapy. J. Immunol., 160:4635–4640.
33.
PichavantC., ChapdelaineP., CerriD.G., DominiqueJ.C., QuennevilleS.P., SkukD., KornegayJ.N., BizarioJ.C., XiaoX., TremblayJ.P.2010. Expression of dog microdystrophin in mouse and dog muscles by gene therapy. Mol. Ther., 18:1002–1009.
TrolletC., SchermanD., BigeyP.2008. Delivery of DNA into muscle for treating systemic diseases: Advantages and challenges. Methods Mol. Biol., 423:199–214.
39.
VilquinJ.T., WagnerE., KinoshitaI., RoyR., TremblayJ.P.1995. Successful histocompatible myoblast transplantation in dystrophin-deficient mdx mouse despite the production of antibodies against dystrophin. J. Cell Biol., 131:975–988.
40.
VilquinJ.T., KennelP.F., Paturneau-JouasM., ChapdelaineP., BoisselN., DelaereP., TremblayJ.P., SchermanD., FiszmanM.Y., SchwartzK.2001. Electrotransfer of naked DNA in the skeletal muscles of animal models of muscular dystrophies. Gene Ther., 8:1097–1107.
41.
WangB., LiJ., QiaoC., ChenC., HuP., ZhuX., ZhouL., BoganJ., KornegayJ., XiaoX.2008. A canine minidystrophin is functional and therapeutic in mdx mice. Gene Ther., 15:1099–1106.
42.
WangZ., KuhrC.S., AllenJ.M., BlankinshipM., GregorevicP., ChamberlainJ.S., TapscottS.J., StorbR.2007. Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. Mol. Ther., 15:1160–1166.
WolffJ.A., MaloneR.W., WilliamsP., ChongW., AcsadiG., JaniA., FelgnerP.L.1990. Direct gene transfer into mouse muscle in vivo. Science, 247:1465–1468.
45.
XiongF., XiaoS., YuM., LiW., ZhengH., ShangY., PengF., ZhaoC., ZhouW., ChenH., FangL., ChamberlainJ.S., ZhangC.2007. Enhanced effect of microdystrophin gene transfection by HSV-VP22 mediated intercellular protein transport. BMC Neurosci., 8:50.
46.
ZaissA.K., MuruveD.A.2008. Immunity to adeno-associated virus vectors in animals and humans: A continued challenge. Gene Ther., 15:808–816.
47.
ZhangG., WooddellC.I., HeggeJ.O., GriffinJ.B., HussT., BraunS., WolffJ.A.2009. Functional efficacy of dystrophin expression from plasmids delivered to mdx mice by hydrodynamic limb vein injection. Hum. Gene Ther., 21:221–237.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
